Drug Trial Radar · NCT01310803
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
May 2011
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin as compared to induction with valrubicin only in subjects with CIS of the bladder. The randomization will be 1:1 and subjects will be stratified by tumor type (CIS plus papillary disease vs. CIS only) and time from last bacillus Calmette-Guerin (BCG) failure (\>1 year vs. \<1 year).
Conditions
- Carcinoma in Situ
- Transitional Cell Carcinoma
- Non-muscle Invasive Bladder Cancer
Interventions
VALSTAR - Maintenance TherapyDrug
Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
No Maintenance treatment ( Standard of Care)Other
Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Efficacy of Maintenance Therapy With Valrubicin After Induction With Valrubicin, as Compared to Induction With Valrubicin Only in Subjects With CIS of the Bladder.Time frame: 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
BCG Oncology
Phoenix, Arizona
The Urology Center of Colorado
Denver, Colorado
Urology Associates
Cumberland, Maryland
Delaware Valley Urology
Sewell, New Jersey
Associated Medical Professionals of New York
Syracuse, New York
Urologic Consultants of SE PA
Bala-Cynwyd, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.